Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Price Passes Above Two Hundred Day Moving Average of $0.32

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.32 and traded as high as $0.58. Brainstorm Cell Therapeutics shares last traded at $0.54, with a volume of 365,604 shares traded.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on Brainstorm Cell Therapeutics in a research note on Wednesday, March 27th. They issued a “sell” rating on the stock.

Brainstorm Cell Therapeutics Price Performance

The firm has a market cap of $36.91 million, a P/E ratio of -1.32 and a beta of 0.27. The stock has a 50 day moving average of $0.47 and a 200 day moving average of $0.32.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC bought a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics as of its most recent SEC filing. 14.33% of the stock is owned by institutional investors.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.